As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
Immunity from Moderna Inc.’s Covid-19 vaccine should last at least a year, the company said at the J.P. Morgan Healthcare conference.
Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.
Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.